Detalhe da pesquisa
1.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227777
2.
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
Gastroenterology
; 162(7): 1876-1890, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35122766
3.
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Lancet
; 390(10114): 2779-2789, 2017 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29096949
4.
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
Am J Gastroenterol
; 113(6): 872-882, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29867173
5.
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.
Am J Gastroenterol
; 112(10): 1584-1592, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28071654
6.
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.
Am J Gastroenterol
; 111(12): 1806-1815, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27670599
7.
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Gastroenterology
; 146(4): 941-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24361468
8.
Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
Clin Gastroenterol Hepatol
; 13(5): 940-8.e3, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25245624
9.
Clinical disease activity in the CALM study - Authors' reply.
Lancet
; 391(10129): 1482, 2018 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29676280
10.
Adalimumab induces deep remission in patients with Crohn's disease.
Clin Gastroenterol Hepatol
; 12(3): 414-22.e5, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23856361
11.
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Am J Gastroenterol
; 109(11): 1771-80, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25155227
12.
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.
Am J Gastroenterol
; 112(6): 975, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28417993
13.
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.
Therap Adv Gastroenterol
; 13: 1756284820938960, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32733600
14.
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
J Crohns Colitis
; 13(6): 725-734, 2019 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753371
15.
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
Inflamm Bowel Dis
; 25(9): 1522-1531, 2019 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753510
16.
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
Aliment Pharmacol Ther
; 49(2): 155-164, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506693
17.
Challenges in IBD Research: Pragmatic Clinical Research.
Inflamm Bowel Dis
; 25(Suppl 2): S40-S47, 2019 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31095704
18.
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
Inflamm Intest Dis
; 2(4): 228-235, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30221150
19.
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
J Crohns Colitis
; 12(8): 930-938, 2018 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29697818
20.
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Inflamm Bowel Dis
; 24(5): 932-942, 2018 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29668919